Chen and colleagues also formulated a therapeutic tumor vaccine by self‐assembling dual adjuvants (CpG and short hairpin RNA) and neoantigens into nanocapsules (around 250 nm) potently activating DCs in dLNs and subsequently priming CD8+ T cell immunity.[51] These findings from peptide‐based vaccine nanoformulation provide implications in rational design of effective therapeutic vaccines for cancer treatment. Here, CD8A is linked to neoplasm.